Login or sign up
For business

Dyne therapeutics

4.2Β· 13 reviews
Average ratingGreat
4.2/ 5

Based on 13 reviews

538%
438%
323%
20%
10%
Ask AI

Ask AI about Dyne therapeutics

Generated with AI from 13 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Linda Kadan
Reviews 1

I was initially skeptical about Dyne therapeutics, but after exploring their website and learning more about their research and development efforts, I am truly impressed. The level of dedication and expertise demonstrated by their team is remarkable. Dyne therapeutics is definitely a company to watch in the therapeutics field.

Margaret Blair
Reviews 1

I recently came across a company that is truly making waves in the healthcare industry. Their groundbreaking solutions have the potential to revolutionize therapeutics. The team behind this company is incredibly passionate and knowledgeable. Highly recommend giving them a look!

Michael Falcetti
Reviews 1

I recently came across a company in the healthcare industry and was really impressed with their work. Their website was clean and well-organized, making it easy to find the information I needed. The team behind the company seems to be incredibly dedicated and knowledgeable. Overall, it's refreshing to see a company like this that is truly making a positive impact. Highly recommend!

Michael Ghee
Reviews 1

I can't help but feel impressed by the dedication and passion I see from the team at Dyne therapeutics. Their work in the field of therapeutics is truly remarkable. The website is user-friendly, providing easy access to information about their groundbreaking solutions. Highly recommend!

Luis Gil
Reviews 1

Dyne therapeutics is an amazing company. I am truly impressed with their innovative approach and dedication to improving the lives of patients. Their website is informative and easy to navigate. The team at Dyne therapeutics is composed of talented and passionate individuals who are making a real difference in the field of therapeutics. I highly recommend Dyne therapeutics to anyone looking for groundbreaking solutions in healthcare.

Jess Todarello
Reviews 1

I have been following Dyne therapeutics for a while now and I must say, they are doing an amazing job in the healthcare industry. Their work is truly groundbreaking and has the potential to change lives. The team behind the company is passionate and talented. Highly recommend!

Amanda Vandenbroek
Reviews 1

πŸ‘ Dyne therapeutics is doing a fantastic job in the healthcare industry. Their innovative solutions are changing lives for the better. The team behind Dyne therapeutics is extremely knowledgeable and passionate. I'm really excited to see what they will accomplish in the future. Keep up the good work!

Chambers
Reviews 1

I recently discovered a company that is truly making a difference in the healthcare industry. Their work is innovative and has the potential to revolutionize therapeutics. The team behind this company is brilliant and passionate. I am excited to see what they will achieve in the coming years.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Dyne therapeutics

Repairing muscle, reclaiming now. Life-transforming therapies for inherited muscle diseases.

Dyne Therapeutics: Revolutionizing the Treatment of Inherited Muscle Diseases

Dyne Therapeutics is a biotechnology company that is dedicated to developing life-transforming therapies for inherited muscle diseases. The company was founded in 2018 by a team of experienced scientists and entrepreneurs who recognized the need for innovative treatments for these debilitating conditions.

Inherited muscle diseases are a group of genetic disorders that affect the muscles, causing weakness, wasting, and loss of function. These conditions can be devastating for patients and their families, as they often lead to progressive disability and reduced quality of life.

Dyne Therapeutics is focused on developing therapies that target the underlying genetic causes of these diseases. The company's approach involves using its proprietary technology platform to deliver therapeutic nucleic acids directly to affected muscles, with the goal of repairing or replacing defective genes.

One key advantage of Dyne's approach is its ability to target specific tissues and cells within the body. This precision targeting minimizes off-target effects and reduces the risk of toxicity or other adverse events.

The company's technology platform is based on research conducted at Harvard Medical School by Drs. Eric Olson and Bruce Conklin. This research led to the discovery of a novel class of molecules called "myotonic dystrophy protein kinase (DMPK) binding oligonucleotides" (DBOs), which have unique properties that make them ideal for delivering therapeutic nucleic acids.

Dyne has exclusive rights to this technology platform, which it has further developed through collaborations with leading academic institutions and industry partners. The company has also assembled a world-class team with expertise in genetics, drug development, regulatory affairs, and commercialization.

Currently, Dyne is focused on developing therapies for three inherited muscle diseases: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). These conditions represent significant unmet medical needs, as there are currently no approved treatments available.

DM1 is caused by an expansion in a repetitive DNA sequence within the DMPK gene. This expansion leads to abnormal RNA splicing in affected cells, resulting in toxic RNA molecules that accumulate within cells and cause damage over time. Dyne's lead program aims to develop DBOs that can selectively degrade these toxic RNA molecules while leaving normal RNAs intact.

FSHD is caused by deletions or mutations in a region near chromosome 4q35. This region contains several genes involved in muscle development and function. Dyne's FSHD program aims to develop DBOs that can selectively silence one or more genes within this region without affecting others nearby.

Finally,DMDis caused by mutationsinthe gene encodingdystrophin,a proteinthat playsa critical rolein maintainingthe structuralintegrityofmuscle fibers.Dyne’sprogramfor DMDaimsatdevelopingDBOsthatcaninduceexon skippingto restorefunctionaldystrophininaffectedmuscles.Thisapproachhasbeenvalidatedbyothercompaniesandiscurrentlybeingpursuedbyseveralclinical-stagebiotechfirmsaswellaslargepharmaceuticalcompanies.

In additiontoitsleadprograms,Dyneprovidesapowerfulplatformfortargeteddeliveryoftherapeuticnucleicacids.Thistechnologyhasbroadimplicationsforothergeneticdisordersandcouldpotentiallybeusedtodeveloptherapiesforarangeofconditions,suchascancerandcardiovasculardisease.

Overall,Dynehasthepotentialtorevolutionizethetreatmentofinheritedmusclediseases.Itsscientificexpertise,state-of-the-arttechnologyplatform,andworld-classteammakeitwell-positionedtoadvanceitsleadprogramsintoclinicaldevelopmentandbringlifetransformingtherapiestopatientswhodesperatelyneedthem.Withitscommitmenttoprecisionmedicineandpatient-centeredapproach,Dynehasshownthatitistruelydedicatedtomakingadifferenceinthelivesofthoseaffectedbythesechallengingconditions

Address
830 winter street
Categories
Biotechnology